Skip to main content
Chair of the Board

Jon is a seasoned business executive with over 25 years of experience, including general management of mid to large size organizations, corporate development, business development, product/service development, business operations, and strategy. He has a proven track record for extraordinary revenue growth, operating performance and developing sustainable, thriving organizations.

In 2015, Jon completed nine years as CEO of Maxxam Analytics, Canada’s largest and leading analytical services company serving the energy, environmental, food and DNA markets. Under his leadership the business more than doubled in size and financial performance through business expansion, innovation and a culture of integrity. The business was private equity and management owned prior to its successful sale to global industry leader, Bureau Veritas in January 2014. Jon is now pursuing new opportunities to advance business creation and leadership development in Canada.

Prior to Maxxam, Jon was the founder and president of a business communications services company as well as holding several successful senior leadership roles across a variety of industries and company sizes/stages.

Jon has an MBA from the Ivey Business School and an Honours BA from Queens University. He has served on the Board of ECO Canada as well as the Foreign Affairs and International Trade Cleantech Canada. He is currently a member of the Ivey Business School Advisory Board and the Ivey Leadership Institute Council. Jon is a 2012 Ernst & Young Entrepreneur of the Year® award winner for his successful leadership at Maxxam. He was also awarded a Special Citation for Entrepreneurial Leadership as part of the Ernst & Young Entrepreneur of the Year® National Awards. In 2013, Jon was recognized for his contributions to Canadian industry in the field of chemistry and awarded the Purvis Memorial Award of the Society for Chemical Industry. Jon has been both a regional and national judge for the EY Entrepreneur of the Year® for 2014, 2015 and 2016.

 

FEEDBACK: Patients HCP